EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseÜbersichtsarbeit

Efficacy and Safety of Bisphosphonates for Complex Regional Pain Syndrome

Michael C Ferraro iD, Neil E O'Connell iD, Andreas Goebel iD, Ruaraidh Hill iD, Ffion Curtis iD, Jack Wilkinson iD, Jacqueline R Center iD, Sylvia M Gustin, Aidan G Cashin iD, James H McAuley iD

Annals of Internal Medicine · 2026-02 · 179 (2) · 256-269

DOI: 10.7326/annals-25-03693 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Annals of Internal Medicine, 2026-02. Verfasst von Michael C Ferraro und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Health Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, and Centre for Pain IMPACT, Neuroscience Research A…. Hauptthemen laut MEDLINE: Diphosphonates, Complex Regional Pain Syndromes, Bone Density Conservation Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Clinical guidelines recommend bisphosphonates for complex regional pain syndrome (CRPS) despite limited evidence of efficacy. PURPOSE: To determine the efficacy and safety of bisphosphonates compared with placebo for CRPS. DATA SOURCES: MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and 3 trial registries from inception to 16 September 2025. STUDY SELECTION: Randomized controlled trials enrolling adults with CRPS (type I or II) to bisphosphonate treatment or placebo. DATA EXTRACTION: Primary outcomes were pain intensity and adverse events. Data were synthesized with random-effects meta-analyses. Risk of bias and certainty of evidence were assessed using the Cochrane Risk of Bias 2 Tool and GRADE (Grading of Recommendations Assessment, Development and Evaluation). DATA SYNTHESIS: Eleven trials (754 participants; CRPS type I, 97%), evaluating alendronate (n = 2), clodronate (n = 1), neridronate (n = 5), pamidronate (n = 1), and zoledronate (n = 2), were included. Bisphosphonates may result in little to no difference in pain intensity in the immediate term (≤4 weeks; 0-to-100 scale; mean difference [MD], -9.1 [95% CI, -19.2 to 1.1]; low certainty). In the short term (>4 weeks to 3 months; primary time point), bisphosphonates may reduce pain intensity (MD, -10.0 [CI, -18.9 to -1.1]; low certainty), and in the medium term (>3 to 6 months), they may result in little to no difference in pain intensity (MD, 8.0 [CI, -15.4 to 31.4]; low certainty). The evidence is very uncertain about the effects of bisphosphonates on pain intensity in the long term (>6 months; MD, -2.5 [CI, -19.6 to 14.6]). Bisphosphonates probably increase risk for adverse events (risk ratio, 1.1 [CI, 1.0 to 1.2]; moderate certainty). LIMITATIONS: High heterogeneity and uncertain medium- and long-term effects. Evidence mostly applies to CRPS type I and includes non-U.S.-approved formulations (neridronate, clodronate). CONCLUSION: Bisphosphonates may reduce CRPS pain intensity in the short term, but treatment is accompanied by adverse events. Future research should resolve uncertainty around which patients with CRPS are most likely to benefit from bisphosphonates. PRIMARY FUNDING SOURCE: None. (PROSPERO: CRD42024559783).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DiphosphonatesComplex Regional Pain SyndromesBone Density Conservation AgentsHumansRandomized Controlled Trials as Topic

Substanzen

DiphosphonatesBone Density Conservation Agents

Autor:innen und Institutionen

  • School of Health Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, and Centre for Pain IMPACT, Neuroscience Research Australia, Randwick, New South Wales, Australia (M.C.F., A.G.C., J.H.M.…
  • Department of Health Sciences, Centre for Health and Wellbeing Across the Lifecourse, Brunel University of London, Uxbridge, United Kingdom (N.E.O.).
  • Pain Research Institute, University of Liverpool, and Walton Centre NHS Foundation Trust, Liverpool, United Kingdom (A.G.).
  • Liverpool Reviews and Implementation Group, Health Data Science, University of Liverpool, Liverpool, United Kingdom (R.H., F.C.).
  • Centre for Biostatistics, Manchester Academic Health Science Centre, Division of Population Health, Health Services Research, University of Manchester, Manchester, United Kingdom (J.W.).
  • Garvan Institute of Medical Research and St Vincent's Clinical School, Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia (J.R.C.).

ORCID-Profile: Michael C Ferraro, Neil E O'Connell, Andreas Goebel, Ruaraidh Hill, Ffion Curtis, Jack Wilkinson, Jacqueline R Center, Aidan G Cashin, James H McAuley

Zitieren

APA

Ferraro, M. C., O'Connell, N. E., Goebel, A., Hill, R., Curtis, F., Wilkinson, J., Center, J. R., Gustin, S. M., Cashin, A. G., & McAuley, J. H. (2026). Efficacy and Safety of Bisphosphonates for Complex Regional Pain Syndrome. Annals of Internal Medicine, 179(2), 256-269. https://doi.org/10.7326/annals-25-03693

Vancouver

Ferraro MC, O'Connell NE, Goebel A, Hill R, Curtis F, Wilkinson J, et al. Efficacy and Safety of Bisphosphonates for Complex Regional Pain Syndrome. Annals of Internal Medicine. 2026;179(2):256-269. doi:10.7326/annals-25-03693

BibTeX
@article{Ferraro2026,
  author = {Ferraro, Michael C and O'Connell, Neil E and Goebel, Andreas and Hill, Ruaraidh and Curtis, Ffion and Wilkinson, Jack and Center, Jacqueline R and Gustin, Sylvia M and Cashin, Aidan G and McAuley, James H},
  title = {Efficacy and Safety of Bisphosphonates for Complex Regional Pain Syndrome},
  journal = {Annals of Internal Medicine},
  year = {2026},
  volume = {179},
  number = {2},
  pages = {256--269},
  doi = {10.7326/annals-25-03693}
}
Kostenlos starten →